Introduction

31
Current regulatory approaches for assessing chemicals typically evaluate one chemical at a time, which fails 32 to take into account the human real-world scenario of low-dose exposures to multiple chemicals. Since a 33 growing body of evidence now suggests that simultaneous exposure to many chemicals at doses not 34 singularly causing any effects can add up to induce adverse outcomes [1, 2] , the current regulatory 35 approaches are inadequate. Due to the complexity of the issue, the implementation of methodologies for risk 36 assessment of chemical cocktails remains a challenge, hindering the urgent need to improve chemical risk 37 assessments. Here, we present a pragmatic step-by-step procedure for mixture risk assessment (MRA) and 38
propose approaches for grouping of chemicals. 39 40 3 2. Current status of mixture risk assessment 41 2.1 Additive mixture effects 42 Experiments have shown that chemicals, when exerting similar effects, typically act in a dose-additive 43 manner, and far less frequently in synergistic or antagonistic ways [3, 4] . This means that the efficacies of 44 chemicals in a mixture can be added together, as long as the potency of the individual chemicals is 45 appropriately accounted for. As dose-response curves are usually sigmoidal, the combination of many 46 chemicals at low levels (located at the lowest horizontal part of the dose-response curve) can give rise to a 47 pronounced adverse mixture effect (corresponding to a move up to the steeper part of the dose-response 48 curve). This phenomenon has been observed in cellular systems [5] and animal studies [6] [7] [8] . 49 50 Synergistic or antagonistic interactions are well-known occurrences in drug therapy, where it is common to 51 see drugs either enhancing or inhibiting each other's effect, primarily due to toxicokinetic mechanisms [9] . 52
In contrast, kinetic interactions are much less likely with environmental chemicals, as human exposure levels 53 typically are much lower [10, 11] . Thus, it seems reasonable to anticipate additive effects caused by real-life 54 exposures to environmental chemicals in most cases. 55
56
Over the last decade, public authorities such as the US-Environmental Protection Agency (US-EPA), the 57 Agency for Toxic Substances and Disease Registry (ATSDR), the World Health Organization (WHO), the 58 non-food Committees of the European Commission, and the European Food Safety Authority (EFSA) have 59 all made considerable progress towards developing pragmatic frameworks that are "fit for purpose" and 60 tiered, to deal with combined exposure to multiple chemicals for risk assessment purposes [12] [13] [14] [15] [16] . 61
62
The assumption that chemicals act additively and behave as if they were a simple dilution of each other has 63 resulted in the development of methods for cumulative risk assessment using various approaches: Hazard 64 Index (HI), point of departure index (PODI), relative potency factors (RPF) and toxicity equivalency factors 65 (TEF). These relatively simple tools form a good basis for development of the future paradigm for MRA. 66
Currently, EFSA is compiling the available knowledge on methodologies used to perform mixture risk 67 assessments for human health, animal health and ecological mixture risk assessment [17] . They present a 68 tiered approach to a component based mixture risk assessment using principles of dose addition. HI 69 calculation is considered a first tier summing hazard quotients (HQ) for all components regardless of 70 toxicological endpoint. In the next tier, a refined HI approach takes into consideration that not all the 71 components have the same adverse effect/target organ. A target organ toxicity dose is derived for each end-72 point to estimate an end-point-specific Hazard Index [17] . 73 74 However, as we see data gaps on single chemicals as the major bottleneck for MRA, we suggest a more 75 specific workflow that allows the use of predicted or estimated hazard and exposure data for data-poor 76 chemicals. The philosophy behind this is that risk assessment of chemicals would be greatly improved by 77 taking mixture effects into account, even if great uncertainties are introduced for data-poor chemicals, and 78 that this is better than doing nothing. Real-life human exposure is highly variable and temporally dynamic, both at the individual and population 83 levels. In spite of this, human exposures via the food is traditionally estimated using average intake levels of 84 the chemicals, which is a deterministic method that does not incorporate information about the variability of 85 real exposures. In order to reflect a more realistic exposure scenario, probabilistic exposure models are 86 currently being developed and used for MRA [3, 18, 19 ]. In the same way, new tools for probabilistic hazard 87 assessment are also being developed, which can be very useful for data-rich chemicals such as pesticides. 88
However, for the vast majority of environmental or industrial chemicals, there is a lack of toxicity and 89 exposure data; and since it is unrealistic to obtain 'perfect data' for most chemicals within the foreseeable 90 future, probabilistic models may not be the best way forward for a pragmatic MRA of real-world mixtures 91 within foreseeable future. This means that we currently are forced to perform MRA based on 'average' 92 exposure and hazard data. 93 94 2.3 Bottlenecks for mixture risk assessment 95 One major challenge for MRA is that exposure to multiple chemicals currently is considered under different 96 pieces of legislation, also known as regulatory silos, such as REACH or the EU pesticides Regulation 97 [20, 21] . Typically, humans are exposed to multiple chemicals from multiple sources, which can give rise to 98 mixture effects, i.e. they can elicit similar effects or exhibit the same mode of action [22] . However, these 99 chemicals may be risk assessed, risk managed or regulated by different authorities based on the legislations 100 to which the chemicals belong. Thus, legal mandates for performing MRA across regulatory silos and 101 legislations are needed, as are pragmatic MRAs allowing for cross-silos assessments. 102 103 Data gaps for individual chemicals seem to be a major issue when it comes to dealing with MRA, both 104 regarding hazard and exposure data. In an attempt to address the lack of toxicity data, we suggest a 105 pragmatic approach with a focus on how to derive information on hazards in cases where data are scarce and 106 on methodologies for grouping of chemicals for MRA. 107 108 3. A pragmatic approach for mixture risk assessment 109 We have constructed a decision tree outlining a step-by-step procedure for MRA based on the use of Hazard 110 Index (HI) (Fig. 1 ). This approach can be used to obtain a conservative (cautious) starting level for overall 111 conclusions, and only progress to more refined methods including effect-based grouping of chemicals in 112 cases where an initial concern for human toxicity is identified. This approach differs from previously 113 suggested 'tiered' approaches [14, 23] , in which crude estimates with a high degree of caution are performed 114 at early tiers in data poor situations, whereas higher tiers use more refined approaches with increasing data 115 demand and higher certainty. However, since mixtures will usually contain both data-rich and data-poor 116 6 chemicals, we need to be able to derive a HI for mixtures of chemicals with information of various refined 117
levels. 118
Our suggestion for a pragmatic MRA approach is shown in Figure 1 Have the sources been identified? Can exposure via the food be estimated from contaminant data for specific 132 food items? Furthermore, it needs to be considered whether mean or median exposure values, or 95% 133 percentiles should be applied in the given situation. 134 135 2. Hazard quotients (HQs) are calculated as the ratio between exposure estimate and RfV for a given 136 substance based on the collected data in step 1. We suggest allowing the use of HQs calculated from relevant 137 in vitro data and for instance human biomonitoring data. An example of this can be found in Johansson et al. 138 (2019) in this issue. If the HQ is above or close to 1 for any single chemical, the decision to regulate is 139 handed over to the regulatory bodies. If all HQs are less than 1, proceed to step 3. 140 141 3. At this step, it is considered whether deviations from dose additivity can be expected. Are there reasons to 142 suspect that interaction between the chemicals will occur by toxicodynamic or toxicokinetic interactions? for summing up all hazards irrespective of effects is based on considering the human body as one complex 150 organism, as well as the hypothesis that various toxicities are often interrelated. A major limitation of this 151 step is a high degree of inherent uncertainties when setting RfV and exposure estimates for each chemical in 152 the mixture. In addition, it is acknowledged that use of the dose-addition principle is not precise for chemical 153 mixtures for which different endpoints have been used for deriving RfVs. If the calculated HI exceeds 1, it 154
will be necessary to group the chemicals according to their specific toxicities (step 5). In cases where the HI 155 becomes less than 1, proceed to step 6. 156 157 5. For mixtures with a non-refined HI higher than 1, it is necessary to group the chemicals according to effect 158 or mode-/mechanism-of-action using available in vivo, in vitro or in silico data (see below). For each group 159 of chemicals, a more specific and refined HI is calculated. If any of these HI's exceeds 1, regulatory action 160 should be decided upon by the authorities. For those HI's that are less than 1, proceed to step 6. 161 162 6. For HIs less than 1, with or without grouping, it should be considered whether other sources of the same 163 chemicals exist or if other chemicals are present that are likely to contribute to the mixture effect. If so, it 164 should be accounted for as described in step 7. If not, no human risk is anticipated for the mixture. adjusted to take this extra contribution (X) into account, i.e. to a cut-off of (1-X). For example, for a specific 168 mixture obtained via the diet, it may be estimated that humans are exposed to the same chemicals from other 169 sources such as via inhalation or via dermal absorption and that these would contribute with 30% of the 170 acceptable risk. Then, the cut-off for acceptable risk for the evaluated mixture is adjusted to 70% (0.7) 171 instead of 1. If the HI < (1-X) where X designates the extra contribution, then no human risk is anticipated. 172
In this example, a HI below 70% would be deemed acceptable. If the calculated HI exceeds (1-X), it will be 173 necessary to group the chemicals according to their specific toxicities as described in step 5. Thus, using this 174 example a HI above 70% would lead to (re-) evaluation of the possibility of grouping mixture components 175 according to shared effects or modes of action (step 5). If any of the HI's exceeds the adjusted cut-off value 176 after grouping of the chemicals, regulatory action should be decided upon by the authorities. If all HI's are 177 still below the adjusted cut-off value after grouping, then no human risk is anticipated for the mixture. Furthermore, EFSA has presented cumulative assessment groups (CAGs) for pesticides with effects on either 185
the nervous system or the thyroid hormone system [26], and CAGs for several other target organs have been 186 proposed by Nielsen et al. 2012 [27] . This approach is limited to chemicals for which in vivo data exist. As 187 an alternative, grouping based on common modes of action may include grouping ofcompounds that act on 188 the same adverse outcome pathways (AOPs). An AOP describes a sequence of events from initial 189 interaction(s) of a stressor with a biomolecule (molecular initiating event), causing perturbations which can 190 progress through a series of intermediate key events and culminate in an adverse outcome [28] . In the future, 191 complex AOP networks may be a preferred methodology for grouping of chemicals, but requires the 9 development of a more densely populated AOP wiki (https://aopwiki.org/). Until such time, we suggest to 193 use empirical in vivo and in vitro data, read-across as well as computational methods such as QSAR models 194 or integrative systems biology. These latter non-test methods can be used to predict inherent hazards or 195 modes/mechanisms of action and to group the chemicals in cases where no experimental data exist. Profiling of chemicals across a panel of in vitro tests was previously applied to explore whether structurally 200 related chemicals share the same mechanism of action. As shown in Fig. 2A, a Another grouping approach is the use of computer models known as QSARs (Quantitative Structure-Activity 211 Relationships). QSARs estimate the relationship between the structure of chemical substances and another 212 property such as the ability to cause toxic effects. QSAR models can therefore be used to predict hazards of 213 chemicals with no or insufficient test data. Figure 2B depicts an example of a QSAR screening performed on 214 2,076 chemicals from food contact materials, including predictions for genotoxic carcinogenicity, 215 mutagenicity, and developmental toxicity [33] . Detailed information on the applied decision-algorithms and 216 the performance of the individual models has been described previously [34] . The figure shows the number 217 of chemicals predicted to be active for each hazard as well as the overlap between the three hazards, which 218 provides a basis for grouping of the chemicals. The free Danish QSAR database can be searched for 219 estimates related to e.g. metabolism and toxicity for more than 600,000 chemicals (http://qsar.food.dtu.dk/). 220
This database is part of the OECD QSAR Toolbox, a software application which incorporates information 221 and tools from various sources (https://www.qsartoolbox.org/home). 222 'Read across' is one of the most commonly used alternative approaches for filling data gaps in registrations 223 for REACH and entails the use of relevant information from analogous chemicals to predict for instance 224 hazards for the chemical in question [35, 36] . Thus, chemicals whose toxicological properties are likely to be 225 similar or follow a regular pattern as a result of structural similarity may be considered a category [36] ). The 226 read-across hypothesis needs to be justified by scientifically credible explanations and sufficient supporting 227 information such as information from QSARs or experimental data addressing specific aspects of the read-228 across hypothesis [36] . Many tools for read-across assessment are available, and in this regard the OECD 229
Toolbox is most advanced in terms of addressing current regulatory needs [37] . 230 231 4.3 Grouping based on a systems biology approach 232 A third approach for grouping chemicals is by use of systems biology approaches ( Fig 2C) . Advanced 233 bioinformatics tools can be used to gain mechanistic knowledge by taking advantage of already existing 234 information about associations between human targets and chemicals. For example, Kongsbak et al [38, 39] , 235 retrieved information for known chemical-protein associations from two publicly available databases, the 236 Comparative Toxicogenomics Database (CTD) [40] and ChemProt 2.0 [41]. This type of analysis gives an 237 overview of known and potential human targets for the chemicals of interest. If chemicals in a mixture then 238 turn out to target the same molecules or are significantly associated with the same disease, or affect the same 239 signaling pathway, it is likely that these chemicals can be allocated to the same group for MRA. In Figure  240 2C, it is illustrated how mancozeb can be excluded from the group, as this chemical belongs to its own 241 network. 242
In conclusion, there are several ways of grouping chemicals, which should be used and explored in more 243 detail for MRA of chemicals. 244 11 245
Perspectives
246
Although several proposals have been published for how to handle risk assessments of chemical mixtures, no 247 consensus has been reached. Given the complexity of MRA and the potential human health risk not 248 accounted for, we propose a pragmatic approach. On the one hand this approach will improve on chemical 249 risk assessment, but on the other require that we accept some uncertainties in the evaluations. The HI is not 250 necessarily an accurate indicator of risk as it is based on hazard and exposure values that are subject to 251 uncertainty. Nevertheless, it provides a low-input, straightforward risk assessment tool that is an 252 improvement compared to the alternative of performing single-chemical risk assessments. 253
254
An important limitation of current MRA is the lack of data on individual chemicals, both with regard to 255 human exposure and toxicity data. To date, only a minor fraction of the many thousands of chemicals in 256 current use have been evaluated and allocated an ADI, TDI, NOAEL, or similar. There is thus an urgent need 257 to address this lack of toxicity data and a way forward could be to develop alternative ways of risk assessing 258 chemicals based on for instance defined panels of in vitro models, or computational tools such as QSARs 259 and physiologically-based kinetic modelling. 260
Our proposal is designed to prevent bottlenecks such as lack of data on individual chemicals or complex real-261 life exposures stopping us from performing a pragmatic MRA of chemicals. 262 263 chemicals, which means that this compound can be excluded from the mixture in a grouping exercise [34] . 402
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